This story is from the CurrentWire archive. Coverage details reflect the last time it was updated.
HYTN Announces Arrangement Agreement to Facilitate the Spin-Out of a Peptide-Focused Drug Development Business
VANCOUVER, British Columbia, Sept. 02, 2026 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC Pink: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, announces that it has entered into an arrangement agreement with Peptide Development Labs Inc. (“PDL”) dated September 1, 2026 (the “Arrangement […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 28 minutes later, on .
Filed under Business · Canada · Press release. Topics extracted from this report, with other live CurrentWire stories mentioning each: Vancouver (1), British Columbia (1), Arrangement Agreement (none), Peptide-Focused Drug Development Business (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.